A Study of Home-Delivered Neurostimulation for Migraine

Status Completed

Clinical Trial Summary

There is a need for better preventive and abortive therapies for migraine. Previous research has indicated that non-invasive neurostimulation may have prophylactic effects on migraine and improve symptoms and functional outcomes in migraineurs. One such method is a non-invasive transcranial direct current stimulation (tDCS). This double-blind randomized sham-controlled two-parallel-arm study aims to evaluate efficacy and safety of tDCS self-delivered in daily 20-minute applications for 2 months (60 days) by adult migraine patients at home for migraine prevention and migraine symptom management, as compared to sham tDCS application; and to evaluate patients' satisfaction with the procedure.

Clinical Trial Description

This study will employ a double-blind randomized sham-controlled two-parallel-arm design and involve 60 adults with migraine. For each participant, the study will involve 3 study visits and last about 90 days (30 days of the baseline followed by 60 days of the tDCS/sham study intervention). A post-study safety monitoring will continue bi-weekly by phone for 30 days after the last tDCS/sham application. At Visit 1, patients will provide written informed consent and undergo screening for the eligibility. This will be followed by 30 days of baseline at home during which patients will keep daily records (Daily Diaries) of migraine occurrence and provide answers to a set of symptom-related questionnaires. Patients with 4 or more migraine days per month who fully meet the study eligibility criteria at the end of the baseline period will be randomized in double-blind manner into two groups: Group 1 will be randomized to receive active tDCS in daily 20-minute applications for 60 days; Group 2 will be randomized to receive sham tDCS in daily 20-minute applications for 60 days, self-applied at home. Following randomization, patients will continue keeping the Daily Diaries and Visit #2 will be held either in the patient's home or in the research facility, based on the patient's preference. tDCS device will be deployed to the patient and instructions on tDCS use will be provided. The first tDCS/sham self-application by the patient will be done at Visit 2. Daily tDCS/sham self-application by the patient at home and records in the form of Daily Diaries will continue for the rest of the 60-day period. Study staff will be in regular remote contact with the patient via phone and/or HIPAA-compliant videoconferencing. Upon conclusion of the intervention, Visit 3 will be held either in the patient's home or in the research facility, based on the patient's preference. tDCS device will be collected from the patient. Safety monitoring will continue bi-weekly by phone for 30 days after the last tDCS/sham application. Outcome assessment will be carried out at the end of the baseline, and at Day 30 (the secondary time-point) and Day 60 (the primary time-point) of the tDCS/sham intervention. ;

Study Design

Related Conditions & MeSH terms

Migraine Disorders

Clinical Trial Details

NCT number	NCT03874351
Study type	Interventional
Source	MJHS Institute for Innovation in Palliative Care
Contact
Status	Completed
Phase	N/A
Start date	April 22, 2019
Completion date	May 12, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01432379` - BOTOX® Prophylaxis in Patients With Chronic Migraine
Completed	`NCT04084314` - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study	Phase 4
Recruiting	`NCT05048914` - Migraine Abortive Treatment
Completed	`NCT03662295` - Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
Completed	`NCT02766517` - Biomarker Study in Participants With Migraine	Early Phase 1
Completed	`NCT00963937` - Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents	Phase 3
Not yet recruiting	`NCT03632928` - Day to Day Variation of Pressure Pain Threshold and Muscle Hardness
Completed	`NCT02559895` - A Multicenter Assessment of ALD403 in Frequent Episodic Migraine	Phase 3
Completed	`NCT01435941` - Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine	N/A
Completed	`NCT00743015` - Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks	Phase 1
Completed	`NCT01376141` - Drug Use Investigation for IMIGRAN Tablet	N/A
Completed	`NCT02183688` - Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients	Phase 3
Completed	`NCT06061588` - "Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches"	N/A
Completed	`NCT03588364` - The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine	N/A
Completed	`NCT04091321` - Association Between Chronic Headache and Back Pain With Childbirth
Completed	`NCT00385008` - TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine	Phase 3
Active, not recruiting	`NCT05888298` - Proximal and Distal Approach GON RFT in Migraine	N/A
Completed	`NCT03435185` - Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients	N/A
Recruiting	`NCT06459635` - Migraine Attack Pain Phase Prediction Study
Completed	`NCT02565186` - An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine	Phase 3